Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
Supply readiness follows months of manufacturing to ensure timely and ample supply
Effective disaster response and management is a collaborative work
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
Subscribe To Our Newsletter & Stay Updated
